Kisqali significantly prolongs life in women with HR+/HER2- advanced breast cancer
Novartis announced Kisqali (ribociclib) achieved statistically significant improvement in overall survival in the Phase III MONALEESA-3 clinical trial . This is the second Phase III clinical trial in which Kisqali combination therapy met the key secondary endpoint of overall survival at the pre-planned interim analysis.
MONALEESA-3 evaluated efficacy and safety of Kisqali plus fulvestrant in postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in both the first-line and second-line settings. No new safety signals were observed; adverse events were consistent with previously reported Phase III trial results.
Kisqali is approved for use in various indications in more than 75 countries around the world.Novartis will present the full results at an upcoming medical congress and submit the data to global health authorities.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins